Inventor

Harpreet Singh

Inventor

Munich, DE

Overview

2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 39 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes17%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations17%

C07KPeptides17%

C12NMicroorganisms or enzymes17%

G01NInvestigating or analysing materials by determining their chemical or physical properties11%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms10%

G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology3%

C12YEnzymes2%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture2%

A01NPreservation of bodies of humans or animals or plants or parts thereof1%

PatentTitleYear

11,027,002Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers2021 11,014,972B*44 restricted peptides for use in immunotherapy against cancers and related methods2021 11,007,258Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers2021 11,007,257Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers2021 11,001,616Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers2021 11,001,617Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods2021 10,967,053Peptides and combination of peptides for use in immunotherapy against various cancers2021 10,954,281Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods2021 10,947,286Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers2021 10,946,081*03 restricted peptides for use in immunotherapy against cancers and related methods2021 10,947,293Peptides and combination of peptides for use in immunotherapy against various tumors2021 10,947,294Peptides and combination of peptides for use in immunotherapy against various tumors2021 10,946,064Personalized immunotherapy against several neuronal and brain tumors2021 10,941,181Immunotherapy against several tumors including neuronal and brain tumors2021 10,934,339Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers2021 10,934,338Peptides and combination of peptides for use in immunotherapy against various tumors2021 10,933,118Immunotherapy against several tumors including gastrointestinal and gastric cancer2021 10,933,125Peptides and combination of peptides for use in immunotherapy against NHL and other cancers2021 10,934,333Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers2021 10,925,947A*03 restricted peptides for use in immunotherapy against cancers and related methods2021 10,925,948Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers2021 10,919,931Immunotherapy against several tumors including neuronal and brain tumors2021 10,905,741Immunotherapy against several tumors including gastrointestinal and gastric cancer2021 10,906,936Immunotherapy against several tumors including neuronal and brain tumors2021 10,899,807Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers2021 10,899,810B*44 restricted peptides for use in immunotherapy against cancers and related methods2021 10,898,558Method of treating with a peptide2021 10,899,813Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods2021 10,898,561Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers2021 10,899,814Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods2021 10,898,557Method of treating with a peptide2021 10,899,806Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers2021 10,899,809Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers2021 10,898,546Immunotherapy against several tumors including gastrointestinal and gastric cancer2021 10,899,808Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers2021 10,899,811B*44 restricted peptides for use in immunotherapy against cancers and related methods2021 10,898,559Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers2021 10,899,812Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods2021 10,898,560Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers2021

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2021Patents assigned to IMMATICS BIOTECHNOLOGIES GMBH (39)· patent assignee history

2021Based in Munich, DE· patent location history

2021Based in Houston, TX, US· patent location history

2021Based in München Schwabing, DE· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
IMMATICS BIOTECHNOLOGIES GMBH	39	2021

Locations

Location	Patents	Span
Munich, DE	33	2021
Houston, Texas, US	4	2021
München Schwabing, DE	2	2021